Andrew Technologies

About Andrew Technologies

Andrew Technologies, LLC, established in 2007, is a medical technology firm operating in the body aesthetics market. The company was founded by Dr. Mark S. Andrew, who also serves as its Chief Scientific Officer. Dr. Andrew is a co-inventor of the company's core technology, leveraging his background to steer the research and development of its primary product.

The company's flagship product is the HydraSolve® Lipoplasty System, a medical device for performing liposuction. This system is sold to plastic surgeons specializing in aesthetic body contouring. The business generates revenue through the sale of these systems. Andrew Technologies launched the HydraSolve® system in the United States in early 2013 after an initial release to select expert surgeons.

HydraSolve® is differentiated by its use of patented Tissue Liquefaction Technology™. This technology, which was previously applied in precision cataract surgery by Alcon in 2003, uses a controlled stream of warmed, low-pressure saline to liquefy targeted fat tissue. Unlike traditional methods that require forceful cutting with a cannula, HydraSolve®'s specialized cannula has rounded edges. The system works by cell disaggregation, meaning it selectively breaks apart fat cells while aiming to preserve surrounding tissues like blood vessels and nerves. This approach is designed to reduce the patient's recovery time, pain, and bruising, while also offering surgeons better control and reduced physical effort. A significant milestone was achieved in 2013 when the FDA cleared the harvested fat tissue for autologous fat transfer, allowing it to be reinjected into the same patient.